

Original Article

Emerging Challenges: High frequency of Antiseptic Resistance Encoding Genes and Reduced Biguanide Susceptibility in Antibiotic-Resistant *Acinetobacter baumannii* in Iran

Ghasemzadeh-Moghaddam, H^{1,3*}, Radmeher, M², Firouzeh, N¹, Moghbeli, M⁴, Azimian, A¹, Salehi, M¹, Fani, M¹, Dashti, V³, Van Belkum, A⁵

1. Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
2. Assistsnt proffesor, Department of Medical Sciences, Bojnourd Branch, Islsmic Azad University, Bojnourd, Iran.
3. Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
4. Department of Microbiology, Damghan branch, Islamic Azad University, Damghan, Iran.
5. Open Innovation & Partnerships, BaseClear, Sylviusweg 74, 2333 BE Leiden, Netherlands.

How to cite this article: Ghasemzadeh-Moghaddam H, Radmeher M, Firouzeh N, Moghbeli M, Azimian A, Salehi M, Fani M, Dashti V, Van Belkum A. Emerging Challenges: High frequency of Antiseptic Resistance Encoding Genes and Reduced Biguanide Susceptibility in Antibiotic-Resistant *Acinetobacter baumannii* in Iran. *Archives of Razi Institute*. 2025;80(1):243-248. DOI: 10.32592/ARI.2025.80.1.243



Copyright © 2023 by



Razi Vaccine & Serum Research Institute

ABSTRACT

Acinetobacter baumannii (*A. baumannii*) has been identified as a prevalent infectious agent that is frequently reported from patients in hospital intensive care units (ICUs). Annually, multi-drug-resistant (MDR) isolates pose a significant clinical challenge. The present study aimed to determine the prevalence of antiseptic resistance genes and the level of resistance to quaternary ammonium and biguanide compounds in *A. baumannii* isolates obtained from patients of north Khorasan province. All obtained *A. baumannii* isolates were examined for in The presence of genes that encode for resistance to antiseptics, including *qacE*, *qacEΔ1*, and *blaOXA-23*, was investigated. The broth microdilution method was utilized to determine the Minimum Inhibitory Concentrations (MICs) against antiseptic compounds. The study found that the majority of *A. baumannii* infections were observed in ICU patients (n=63, 84%). MDR and extensively drug-resistant (XDR) phenotypes were present in 53.2% and 46.7% of cases, respectively. Among 75 isolates, 48 (64%) had at least one resistance gene, including 24 (32%) isolates with only the *qacE* gene and 5 (6.7%) isolates with the *qacEΔ1* gene. Furthermore, the coexistence of the *qacE* and *qacEΔ1* genes was observed in nine (25.3%) isolates. Statistically significant differences were identified in the mean minimum inhibitory concentration (MIC) of chlorhexidine digluconate (CHG) between isolates with and without antiseptic resistance genes (81.4 μg/ml versus 27.9 μg/ml, P=0.001). The heightened minimum inhibitory concentration (MIC) levels exhibited by *A. baumannii* isolates against antiseptic agents constitute a significant medical concern. The presence of antiseptic-resistant genes and elevated MIC levels against antiseptic agents in MDR and XDR *A. baumannii* underscores the imperative for comprehensive monitoring of all *A. baumannii* isolates in hospital settings to ensure efficacious infection control measures.

Article Info:

Received: 1 July 2024

Accepted: 8 September 2024

Published: 28 February 2025

Corresponding Author's E-Mail:
sadeghimasoudkum@gmail

Keywords: *Acinetobacter baumannii*, Multi-Drug Resistant, Antiseptic Resistance, Biguanide Compound, *qacE*, *qacEΔ1*.

1. Introduction

Acinetobacter baumannii is a colonizer of the human ecosystem and a nosocomial infectious agent (1). It is responsible for a variety of infections in the hospital setting, including pulmonary infection, urinary tract infection and meningitis. Multi-Drug Resistance (MDR) and carbapenems resistance among *A. baumannii* isolates from Intensive Care Units (ICU) is a universal dilemma (2). The carbapenem resistance that is the result of genes such as those encoding oxacillinase (OXAs) has led to this class of antibiotics being withdrawn from the first-line drugs of choice for the treatment of *A. baumannii* infections (3). The insertion of gene sequences in the upstream regions of blaOXA-23 genes is responsible for the regulation of carbapenem resistance among *A. baumannii* (4). This highlights the importance of the effective prevention strategies against this microbial species in hospitals. In healthcare settings, disinfectants containing quaternary ammonium compounds (QACs), such as benzethonium chloride (BTC) and benzalkonium chloride (BKC), as well as biguanide compounds like chlorhexidine digluconate (CHG), are widely employed to prevent nosocomial infections. The mechanisms of action of chlorhexidine and QAC, including cytoplasmic membrane disruption and phospholipid bilayer damage, further underscore their efficacy (5). However, it is crucial to acknowledge that prolonged utilisation of these antiseptic agents can lead to the development of resistance in *A. baumannii* through the acquisition of genes such as qacA/B, qacC/D, and qacE (6). Gram-negative bacteria that possess the qacE and qacEΔ1 genes exhibit resistance to QAC (7). The acquisition of antiseptic resistance genes by bacteria that are already resistant to other antibiotics is an evolving issue in hospital settings, necessitating attention and action (8,9). In the present study, the potential correlation between the presence of antiseptic resistance genes and an elevated resistance phenotype against primary antiseptic agents was investigated. To this end, the prevalence of antiseptic resistance genes (according to the most prominent resistance genes) and the Minimum Inhibitory Concentration (MIC) were analysed. MICs of quaternary ammonium compounds and biguanide compounds in *A. baumannii* isolates obtained from various infections in hospitalized patients at the Imam Hassan Hospital (the primary and referral teaching and care facility in the North Khorasan province, Iran).

2. Materials and Methods

2.1. Study Samples

During the study period, all *A. baumannii* isolates responsible for infections in hospitalized patients at Imam Hassan Hospital in North Khorasan Province, Iran, were identified to the species level in the hospital laboratory. This identification was further validated in the microbiology laboratory at the Faculty of Medicine using Gram staining, oxidase testing, motility testing, and assessing their ability to grow at 42°C, following the Clinical and Laboratory

Standard Institute (CLSI) guidelines. Confirmation at the gene level as *A. baumannii* was achieved through the use of a blaOXA51-like PCR assay. All specimens were stored at -30°C in Trypticase Soy Broth (TSB) with 20% glycerol added. Chromosomal DNA was isolated using a DNA extraction kit from Poyagene Azma, Iran, in accordance with the manufacturer's guidelines for subsequent molecular analyses.

2.2. Antiseptic Susceptibility Testing

The assessment of susceptibility to QACs and biguanide compounds (CHG; Sigma-Aldrich, Steinheim, Germany) was conducted utilizing the Mueller-Hinton broth microdilution method (BMD).

2.3. Antibiotic Susceptibility Testing

Antimicrobial susceptibility testing (AST) was conducted on Mueller-Hinton agar from Merck, Germany, utilizing the disk diffusion (Kirby-Bauer) method. The interpretation of zone sizes was based on Clinical and Laboratory Standards Institute (CLSI) guidelines. The following 11 antimicrobial agents were used to differentiate the isolates of *A. baumannii*: cephalosporins (Cefepime, Ceftazidime), carbapenems (Doripenem, Meropenem, Imipenem), tetracyclines (Tigecycline), β-lactamase inhibitors (Ampicillin+Sulbactam, Piperacillin+Tazobactam), aminoglycosides (Amikacin, Tobramycin) and fluoroquinolones (ciprofloxacin). The isolates were classified as extensively drug-resistant (XDR) if they demonstrated resistance to one or more antimicrobial agents in at least six categories, or if they were resistant to all antibiotics except one or two. Bacteria were grouped as multi-drug resistant (MDR) if they demonstrated resistance to one or more agents in three or more categories.

2.4. Detection of Genes

The screening of all collected samples was conducted in accordance with established methodologies for the identification of antiseptic and antibiotic resistance genes, including the qacE, qacEΔ1, and blaOXA-23 genes (8). The primer sequences employed are enumerated in Table 1.

2.5. Statistics

The data analysis was conducted utilizing the SPSS 17 for Windows (SPSS Inc., Chicago) software. The determination of differences among the isolates was accomplished through the implementation of One-way ANOVA, with P-values less than 0.05 being designated as statistically significant.

3. Results

In the present study, 75 *A. baumannii* isolates were utilized, with the understanding that these isolates were obtained from a variety of clinical specimens, including urine (2 isolates, 2.6%), wounds (5 isolates, 6.6%), blood (4 isolates, 5.3%), and tracheal aspirates (63 isolates, 87%) (Table 2). The demographic profile of the infected patients revealed that 60% of the subjects were male (n=45/75), with a mean age of 65.4 years (range: 22-92 years). The mean age for males was 67.7 years (range: 22-92 years), while for

Table 1. Primer sequence for studied genes.

NO	Oligo Name	Seq(5-3)
1	<i>bla OXAlIike-51F</i>	TAATGCTTTGATCGGCCTTG
2	<i>bla OXAlIike-51R</i>	TGGATTGCACTTCATCTTGG
3	<i>qac E F</i>	ATGAAAGGCTGGCTT
4	<i>qac E R</i>	TCACCATGGCGTCGG
5	<i>qacEΔ1 F</i>	TAGCGAGGGCTTTACTAAGC
6	<i>qacEΔ1 R</i>	ATTCGAAATGCCGAACACCG

Table 2. Demographic data of *A. baumannii* infections.

Gender	Age(year)	Ward							Site of infection				
		ICU			No./percent				No./percent				
No (%)	Mean Rang	I	II	III	NERO	EMR	INF	CARD	LC	WC	BC	UC	other
Male 45(60)	67.7	30 40	6	0	3	3	2	1	36	3	4	2	0
	22-92		8	0	4	4	2.6	1.3	48	4	5.3	2.6	0
Female 30 (40)	63.1	16	10	1	1	1	1	0	27	2	0	0	1
	22-83	21.3	13.3	1.3	1.3	1.3	1.3	0	36	2.6	0	0	1.3
Total 75 (100)	65.4	46	16	1	4	4	3	1	63	5	4	2	1
	22-92	61.3	21.3	1.3	5.3	5.3	4	1.3	84	6.6	5.3	2.6	1.3

ICU: Intensive care unit, CARD: Cardiology, EMR: Emergency, INF: Infectious diseases, NERO: Neurology, LC: tracheal aspirate culture, BC: blood culture, UC: urine culture, WC: wound culture

females it was 63.1 years (range: 22-83 years) (Table 2). The preponderance of *A. baumannii* infections was observed to occur in the ICU (n=63, 84%), with a further breakdown of ICU I (n=46, 61.3%), ICU II (n=16, 21.3%), and ICU III (n=1, 1.3%). The remaining *A. baumannii* infections were detected in the Neurology ward (n=4, 5.3%), the Emergency ward (n=4, 5.3%), the Infectious Diseases ward (n=3, 4%), and the Cardiology ward (n=1, 1.3%). The primary isolation sites of *A. baumannii* isolates were the lungs (84%), followed by wounds (6.6%), blood (5.3%), urine (2.6%), and other (1.3%) (Table 2).

3.1. Antibiotic Susceptibility Test (AST)

The present study examined the antibiotic resistance patterns of *A. baumannii* isolates. The results revealed that the majority of the isolates (96%) demonstrated resistance to at least nine out of the twelve tested antibiotics. The highest and lowest resistance rates were observed for CAZ (98.7%) and TGC (34.7%), respectively. The analysis identified five distinct antibiotic resistance patterns (A-E). Four of these patterns included XDR phenotypes, with pattern A being the only exception (Table 3). Pattern A was the most prevalent resistance pattern, being detected in 31 isolates (41.3%). The *A. baumannii* isolates exhibiting pattern A demonstrated resistance to ten antibiotics (Table 3). XDR isolates were identified among pattern B (11 antibiotics) (N=19, 25.3%), pattern C (nine antibiotics) (N=12, 16%), pattern D (10 antibiotics) (N=6, 8%), and pattern E (11 antibiotics) (N=3, 4%) (Table 2). Four isolates demonstrated a unique resistance pattern. The ICU patients exhibited the highest number of *A. baumannii* infections (75 patients in total, with 63 infections, constituting 84%). Among these patients were 36 males (57%) and 27 females

(43%). The majority of cases exhibited MDR (Multi Drug Resistant) and XDR (Extended Drug Resistant) phenotypes, with 62 cases (98.4%) demonstrating these traits (53.2% MDR and 46.7% XDR).

3.2. Antiseptic Resistance Gene Distribution

In the present study, a total of 75 isolates were analysed, of which 48 (64%) were found to have at least one antiseptic resistance gene. This included 24 isolates (32%) with the *qacE* gene, five isolates (6.7%) with the *qacEΔ1* gene, and nine isolates (25.3%) where both *qacE* and *qacEΔ1* genes were detected simultaneously. The highest prevalence of antiseptic resistance genes (*qacE* and *qacEΔ1*) was detected in pattern D (100%), followed by pattern B (68.4%), pattern A (64.5%), and pattern C (58.3%). The most prevalent single occurrence of *qacE* (83.3%) and *qacEΔ1* (66.7%) genes was observed in pattern D, while in pattern D, there was a simultaneous occurrence of resistance genes at the highest rate of 50%.

3.3. Antibiotic Resistance Gene Distribution

The *BlaOXA-23* gene was identified in 63 (84%) of the isolates examined, with the majority of these isolates also possessing at least one antiseptic resistance gene (n=41/63, 65%). The highest occurrence of the *BlaOXA-23* gene was among pattern D (100%), followed by pattern B (89.4%), pattern A, and pattern C (83.3%) isolates (Table 3).

3.4. MICs for Antiseptics

It is noteworthy that there was no statistically significant variation among the isolates with respect to BTC and BKC resistance levels, suggesting a uniformity in the patterns of resistance exhibited. The MICs for various antiseptics ranged from 3.9 to 31.2 µg/ml for BTC, from 3.9 to 62.5 µg/ml for BKC, and from 31.2 to 250 µg/ml for CHG. The mean MIC for CHG in isolates with antiseptic resistance

genes was found to be significantly higher than in isolates without these genes (81.4 µg/ml versus 27.9 µg/ml, P=0.001). Furthermore, a statistically significant difference in mean MICs for CHG was observed among isolates harboring *qacE* (63.8 µg/ml), *qacEΔ1* (56.2 µg/ml), and *qacE+qacEΔ1* (111.8 µg/ml) in comparison to those not possessing these genes (27.9 µg/ml, P=0.001). Moreover, the investigation revealed that 63 out of 75 (97.3%) isolates possessed the *blaOXA-23* gene, with 41 out of 63 (65%) of these isolates also harboring at least one additional antiseptic resistance gene (Table 4).

4. Discussion

The present study results illustrate the correlation between the antiseptic resistance genes (*qacE* and *qacEΔ1*) and minimal inhibitory concentrations (MICs) against CHG. The prevalence of multidrug resistance (MDR) and extensively drug resistance (XDR) (94.6%) is higher than reported from other parts of Iran. The MDR prevalence ranges between 32.7% and 93% (2001 to 2011 among Iranian *A. baumannii* isolates reported by seven studies) (10). A recent study by Mirzayi and colleagues (2020) reported 74.8% and 73.1% prevalence of MDR and XDR,

respectively (11). The MDR phenotype rate was reported from 50% to 85% from Latin American countries, Africa, Asia, and North American countries (12). The high prevalence of MDR isolates from intensive care unit (ICU) wards noted in this study aligns with findings from other research, except in North American countries (12). Resistance against carbapenems detected in the current study was reported differently in European and Arabian countries (13). Elevated resistance against carbapenems was also reported in Iran (14). The prevalence of the *qacEΔ1* gene reported in the present study is significantly lower than in several other studies conducted in Iran (49.5%, 59%, and 91%) and other countries (63% - 96.07% (15,16)). Some Iranian studies reported a higher frequency of the *qacE* gene (40% - 47.5%) (17,18), while its rate was reported to be lower (4% - 17%) in other Iranian studies (19). The prevalence of the *qacE* gene among *A. baumannii* isolates has been reported to be higher in other countries (33.3% from Saudi Arabia) (20), 45.5% and 52% from Egypt (21), and 73% from Malaysia (22). However, a lower prevalence has been reported in China (30.48% and 31.37%) (8,16). The elevated prevalence of the *blaOXA-23* gene and its carbapenems resistant phenotype documented

Table 3: Antibiotic resistance patterns versus antiseptic and antibiotic resistance gene distribution among *A. baumannii* isolates.

Pattern No. (%)	Resistant to antibiotic	Sensitive	having at least a gene	<i>qacE</i>	<i>qacEΔ1</i>	<i>qacE+ qacEΔ1</i>	<i>BlaOXA-23</i>	
							No (%)	
A(MDR) 31(41.3)	SAM, FEP, AMI, TOB, PI+TZ, CAZ, MEM, IMI, DOR, CIP 10	TGC 1	20 64.5	17 54.8	12 38.7	9 29	26	83.8
B (XDR) 19 (25.3)	SAM, FEP, AMI, TOB, PI+TZ, CAZ, MEM, IMI, DOR, CIP, TGC 11	- 0	13 68.4	13 68.4	5 26.3	5 26.3	17	89.4
C (XDR) 12 (16)	FEP, AMI, TOB, PI+TZ, CAZ, MEM, IMI, DOR, CIP 9	SAM, TGC 2	7 58.3	6 50	3 25	2 16.6	10	83.3
D (XDR) 6 (8)	FEP, AMI, TOB, PI+TZ, CAZ, MEM, IMI, DOR, CIP, TGC 10	SAM, 1	6 100	5 83.3	4 66.7	3 50	6	100
E (XDR) 3 (4)	SAM, FEP, AMI, TOB, PI+TZ, CAZ, MEM, IMI, DOR, CIP, TGC 11	- 0	1 33.3	1 33.3	0	0	1	33.3

Doripenem(DOR)(10mg), Meropenem(MEM)(10mg), Tigecycline(TGC)(15mg), Imipenem(IMI)(10mg), Ceftazidime(CAZ)(30mg), Ampicillin+Sulbactam (SAM) (20mg), Cefepime(FEP) (30mg), Amikacin(AMI)(30mg), Tobramycin(TOB)(10mg), Ciprofloxacin (CIP), Piperacillin+Tazobactam (PI+TZ).

Table 4. Distribution of antiseptic resistance genes and MIC level among *A. baumannii* isolates.

gene	BTC		BKC		CHG		resistance gene distribution pattern	BTC	BKC	CHG	<i>BlaOXA-23</i>				
	Mean (µg/ml) rang	P	Mean µg/ml Rang	P	Mean µg/ml rang	P						Mean (µg/ml)			
												No. (%)	rang	No. (%)	
Positive 48 (64%)	14.4 3.9-31.2	0.276	20.2 3.9-62.5	0.41	81.4 31.2-250	0.001	<i>qacE</i> 24 (50%)	13.02 (3.9-31.2)	18.8 (7.8-31.2)	62.5 (31.2-125)	20 49.3				
							<i>qacEΔ1</i> 5 (10.4%)	16.4 (3.9-31.2)	16.4 (3.9-31.2)	56.2 (31.2-62.5)	5 28.7				
							<i>qacEΔ1+qacE</i> 19 (39.5%)	15.6 (7.8-31.2)	22.8 (3.9-62.5)	111.8 (62.5-250)	16 21.9				
Negative 27 (36%)	11.5 3.9-31.2		14.6 1.9-62.5		27.9 1.9-62.5			11.5 (3.9-31.2)	14.6 (1.95-62.5)	27.9 (1.9-62.5)					

BlaOXA-23: Antibiotic resistance gene, P: One way ANNOVA test, bold text: significant.

in this study is of particular interest (23). The co-occurrence of antiseptic and antibiotic resistance in our isolates, likely attributable to their co-location within the same class I integron, is a significant concern. This discovery highlights the potential difficulties in eliminating these isolates, emphasising the need for further research in this critical area (24). The frequent detection of antiseptic resistance genes among the blaOXA-23-harboring isolates poses a significant challenge to the eradication of these isolates. A statistically significant increase in the MIC against CHG was detected among qacE- and qacEΔ1-positive *A. baumannii* isolates. Guo et al. documented a statistically significant increase in the MIC against CHG in qacE-positive isolates in China (16). Conversely, Liu et al. observed a non-statistically significant increase in the MIC against BKC among qacE-positive *A. baumannii* isolates (8). Contrary to these findings, studies conducted in Saudi Arabia (20) reported no increase in MIC values among *A. baumannii* isolates against CHG and BTC (8). It is fortunate, however, that the recommended concentration of use for CHG in commercial disinfectants (5000 µg/ml) is still higher than the highest measured MIC in the current study (25). Nevertheless, the increased MIC among *A. baumannii* isolates from our region is a significant clinical concern. The presence of *A. baumannii* isolates with MDR and XDR phenotypes, which possess antiseptic resistance genes and elevated MICs against antiseptic agents, underscores the necessity for meticulous monitoring of all *A. baumannii* isolates in hospital settings.

Acknowledgment

We would like to take this opportunity to express our gratitude to Mrs. Shabnam Shirazii, who works in the diagnostic laboratory at Imam Hassan Hospital in Bojnurd. We are extremely grateful to her for kindly providing us with all the isolates.

Authors' Contribution

Conceptualization, Project Administration, Writing _Original Draft Preparation; HGM. Investigation and laboratory works, NF; Investigation and Resources; M R. Project Administration; MM. Investigation and Resources, and AvB. Writing – Review and Editing, scientific advice; AA.

Ethics

The collection of samples was carried out in strict accordance with the guidelines approved by the Ethical Committee of Islamic Azad University, Damghan, Iran (ethics code: IR.IAU.DAMGHAN.REC.1401.001).

Conflict of Interest

The authors have no relevant financial or non-financial interests to disclose.

Funding

This project was supported by Islamic Azad University, Damghan, Iran (ethics code: IR.IAU.DAMGHAN.REC.1401.001.).

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

References

1. Antunes LCS, Visca P, Towner KJ. *Acinetobacter baumannii*: Evolution of a global pathogen. *Pathog Dis*. 2014;71(3):292–301.
2. Lima WG, Silva Alves GC, Sanches C, Antunes Fernandes SO, de Paiva MC. Carbapenem-resistant *Acinetobacter baumannii* in patients with burn injury: A systematic review and meta-analysis. *Burns*. 2019;45(7):1495–508.
3. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microb Genomics*. 2019;5(10).
4. Hussain EA, Qasim Hameed H, Mujahid Al-Shuwaikh A, Mujahid Abdullah R. Detection of the aadA1 and aac (3)-IV resistance genes in *Acinetobacter baumannii*. *Arch Razi Inst*. 2022;77(3):959–66.
5. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. *Clin Microbiol Rev*. 1999;12(1):147–79.
6. Correa JE, De Paulis A, Predari S, Sordelli DO, Jeric PE. First report of qacG, qacH and qacJ genes in *Staphylococcus haemolyticus* human clinical isolates. *J Antimicrob Chemother*. 2008;62(5):956–60.
7. Paulsen IT, Littlejohn TG, Radstrom P, Sundstrom L, Skold O, Swedberg G, et al. The 3' conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and disinfectants. *Antimicrob Agents Chemother*. 1993;37(4):761–8.
8. Liu WJ, Fu L, Huang M, Zhang JP, Wu Y, Zhou YS, et al. Frequency of antiseptic resistance genes and reduced susceptibility to biocides in carbapenem-resistant *Acinetobacter baumannii*. *J Med Microbiol*. 2017;66(1):13–7.
9. Nima F, Foroughi Borj H, Ziaali N, Tavakoli Kareshk A, Ahmadinejad M, Shafiei R. Genetic Diversity of *Toxoplasma gondii* by Serological and Molecular Analyzes in Different Sheep and Goat Tissues in Northeastern Iran. *Iran J Parasitol*. 2023;18(2):217–28.
10. Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of *Acinetobacter baumannii* in Iran: A systemic review of the published literature. *Osong Public Heal Res Perspect*. 2015;6(2):79–86.
11. Mirzaei B, Bazgir ZN, Goli HR, Iranpour F, Mohammadi F, Babaei R. Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of *Pseudomonas aeruginosa* and *Acinetobacter baumannii*

- isolated in clinical samples from Northeast of Iran. *BMC Res Notes*. 2020;13(1):1–6.
12. Lob SH, Hoban DJ, Sahn DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of *Acinetobacter baumannii*. *Int J Antimicrob Agents*. 2016;47(4):317–23.
 13. Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. *Lancet Infect Dis*. 2018;18(12):e379–94.
 14. Abbasi E, Goudarzi H, Hashemi A, Chirani AS, Ardebili A, Goudarzi M, et al. Decreased *carO* gene expression and OXA-type carbapenemases among extensively drug-resistant *Acinetobacter baumannii* strains isolated from burn patients in Tehran, Iran. *Acta Microbiol Immunol Hung*. 2021;68(1):48–54.
 15. Gomaa FAM, Helal ZH, Khan MI. High prevalence of *bladm-1*, *blavim*, *qace*, and *qaceΔ1* genes and their association with decreased susceptibility to antibiotics and common hospital biocides in clinical isolates of *Acinetobacter baumannii*. *Microorganisms*. 2017;5(2):18.
 16. Guo J, Li C. Molecular epidemiology and decreased susceptibility to disinfectants in carbapenem-resistant *Acinetobacter baumannii* isolated from intensive care unit patients in central China. *J Infect Public Health*. 2019;12(6):890–6.
 17. Khosravi AD, Montazeri EA, Maki SR. Antibacterial effects of Octenisept, and benzalkonium chloride on *Acinetobacter baumannii* strains isolated from clinical samples and determination of genetic diversity of isolates by RAPD-PCR method. *Mol Biol Rep*. 2021;48(11):7423–31.
 18. Mahzounieh M, Khoshnood S, Ebrahimi A, Habibian S, Yaghoobian M. Detection of antiseptic-resistance genes in *Pseudomonas* and *Acinetobacter* spp. isolated from burn patients. *Jundishapur J Nat Pharm Prod*. 2014;9(2).
 19. Keshavarz-Hedayati S, Shapouri R, Habibollah-Pourzerehki N, Bigverdi R, Peymani A. Molecular Investigation of Resistance to Disinfectants in *Acinetobacter Baumannii* Isolates Collected From Qazvin Hospitals, Iran (2017). *J Qazvin Univ Med Sci*. 2019;23(1):2–13.
 20. Vijayakumar R, Sandle T, Al-Aboody MS, AlFonaisan MK, Alturaiki W, Mickymaray S, et al. Distribution of biocide resistant genes and biocides susceptibility in multidrug-resistant *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* — A first report from the Kingdom of Saudi Arabia. *J Infect Public Health*. 2018;11(6):812–6.
 21. Elkhatib WF, Khalil MAF, Ashour HM. Integrons and Antiseptic Resistance Genes Mediate Resistance of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* Isolates from Intensive Care Unit Patients with Wound Infections. *Curr Mol Med*. 2019;19(4):286–93.
 22. Babaei MR, Sulong A, Hamat RA, Nordin SA, Neela VK. Extremely high prevalence of antiseptic resistant quaternary ammonium compound E gene among clinical isolates of multiple drug resistant *Acinetobacter baumannii* in Malaysia. *Ann Clin Microbiol Antimicrob*. 2015;14(1):1–5.
 23. Wong MH yin, Chan BK wai, Chan EW chi, Chen S. Over-Expression of ISAbal-Linked Intrinsic and Exogenously Acquired OXA Type Carbapenem-Hydrolyzing-Class D-β-Lactamase-Encoding Genes Is Key Mechanism Underlying Carbapenem Resistance in *Acinetobacter baumannii*. *Front Microbiol*. 2019;10:486957.
 24. Sabbagh P, Rajabnia M, Maali A, Ferdosi-Shahandashti E. Integron and its role in antimicrobial resistance: A literature review on some bacterial pathogens. *Iran J Basic Med Sci*. 2021;24(2):136–42.
 25. Taheri N, Ardebili A, Amouzandeh-Nobaveh A, Ghaznavi-Rad E. Frequency of antiseptic resistance among *Staphylococcus aureus* and coagulase-negative staphylococci isolated from a university hospital in Central Iran. *Oman Med J*. 2016;31(6):426–32.